1. Home
  2. PRO vs MNMD Comparison

PRO vs MNMD Comparison

Compare PRO & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROS Holdings Inc.

PRO

PROS Holdings Inc.

HOLD

Current Price

$23.25

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Logo Mind Medicine (MindMed) Inc.

MNMD

Mind Medicine (MindMed) Inc.

HOLD

Current Price

$12.91

Market Cap

960.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRO
MNMD
Founded
1985
2019
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Pharmaceuticals and Biotechnology
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
960.2M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
PRO
MNMD
Price
$23.25
$12.91
Analyst Decision
Buy
Strong Buy
Analyst Count
7
9
Target Price
$24.54
$25.78
AVG Volume (30 Days)
1.2M
1.5M
Earning Date
10-27-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$351,682,000.00
N/A
Revenue This Year
$10.50
N/A
Revenue Next Year
$10.86
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.92
N/A
52 Week Low
$13.61
$4.70
52 Week High
$29.84
$14.43

Technical Indicators

Market Signals
Indicator
PRO
MNMD
Relative Strength Index (RSI) 76.65 58.17
Support Level $23.06 $12.19
Resistance Level $23.20 $13.45
Average True Range (ATR) 0.05 0.70
MACD -0.04 0.11
Stochastic Oscillator 95.24 82.75

Price Performance

Historical Comparison
PRO
MNMD

About PRO PROS Holdings Inc.

Pros Holdings Inc provides software solutions that optimize shopping and selling experiences for both business-to-business and business-to-consumer companies across industry verticals in more than nearly 80 countries. Its PROS Platform is designed to help businesses create, optimize and market available offers and handle orders through both first- and third-party digital channels. The firm generates key revenue form the United States of America, Germany, The rest of Europe, Africa, Asia-Pacific, and Middle East regions.

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Share on Social Networks: